This review aims to analyse the available evidence of NADPH oxidase-mediated OS in the context of hyperphosphataemia, highlighting its implications for chronic kidney disease, vascular calcification, metabolic disorders, and cancer. Here, FMO5 is linked to chronic kidney disease.